The on-body injector's fixed, flat-rate dosage simplifies clinical workflow and improves safety by eliminating the need for constant, error-prone dose recalculations based on patient weight changes, which is standard for many body surface area (BSA)-based cancer therapies.

Quantitative data from the ISOLICAL trial reveals an overwhelming patient preference for on-body injectors (OBI) over manual injection. With 75% preferring OBI and 90% choosing it when given an option, patient experience—driven by comfort, reduced pain, and convenience—emerges as a critical factor for technology adoption in oncology.

The primary advantage of subcutaneous amivantamab extends beyond clinical safety to operational efficiency and patient well-being. It significantly reduces infusion time, freeing up limited oncology clinic resources and, more importantly, allowing patients with a limited life expectancy to spend less time in treatment and more with loved ones.

The isatuximab on-body injector (OBI) is more than an in-clinic convenience; it represents a key technological step toward moving oncology treatment out of specialized centers. This could enable care closer to or even at patients' homes, particularly benefiting rural patients who face significant travel burdens.

The intravenous amivantamab regimen has faced adoption challenges due to practical burdens on patients and clinics, including long infusion times, infusion reactions, and scheduling difficulties. The shift to a subcutaneous formulation is a critical step to overcome these non-clinical barriers.

Beyond clinical efficacy, patient experience is a key differentiator. Patients strongly prefer single-administration ("one and done") gene therapies over treatments requiring regular injections. This is due to the cumulative stress, cost, and logistical burden of lifelong, recurring treatments, which directly informs therapeutic modality choice.

Isatuximab previously lagged its competitor, daratumumab, which had a subcutaneous option for years. The new on-body injector (OBI) isn't just about catching up; its efficiency and high patient preference could shift treatment patterns, making it a significant competitive threat and altering its market position.

A key trend in 2025's drug approvals is that "best-in-class" therapies are distinguished not just by efficacy, but by innovations in formulation and delivery that improve the patient experience. Examples include subcutaneous versions of IV drugs and new delivery methods that expand patient access.

Subcutaneous on-body device delivery of anti-CD38 antibodies like isatuximab nearly eliminates the high risk of infusion-related reactions common with intravenous administration, especially during the first dose. This significantly enhances patient safety and comfort in the clinic.